Clin Chem. 2025 Dec 2:hvaf163. doi: 10.1093/clinchem/hvaf163. Online ahead of print. ABSTRACT BACKGROUND: Circulating cell-free DNA (cfDNA) fragmentomic features, such as fragment size and end motifs, have emerged as promising noninvasive biomarkers for cancer detection. However, the influence of nonmalignant clinical factors on these features remains unclear, potentially confounding liquid biopsy assays. METHODS: We analyzed … Read more

Clin Chem. 2025 Dec 2;71(12):1195-1199. doi: 10.1093/clinchem/hvaf097. NO ABSTRACT PMID:41329021 | DOI:10.1093/clinchem/hvaf097

Clin Chem. 2025 Dec 2;71(12):1200. doi: 10.1093/clinchem/hvaf117. NO ABSTRACT PMID:41329020 | DOI:10.1093/clinchem/hvaf117

Clin Chem. 2025 Dec 2;71(12):1201. doi: 10.1093/clinchem/hvaf130. NO ABSTRACT PMID:41329019 | DOI:10.1093/clinchem/hvaf130

Clin Chem. 2025 Dec 2;71(12):1281-1282. doi: 10.1093/clinchem/hvaf106. NO ABSTRACT PMID:41329018 | DOI:10.1093/clinchem/hvaf106

Clin Chem. 2025 Nov 19:hvaf132. doi: 10.1093/clinchem/hvaf132. Online ahead of print. NO ABSTRACT PMID:41259117 | DOI:10.1093/clinchem/hvaf132

Clin Chem. 2025 Nov 13:hvaf162. doi: 10.1093/clinchem/hvaf162. Online ahead of print. ABSTRACT BACKGROUND: Phosphorylated tau 217 (p-tau217) has emerged as a leading blood-based biomarker for Alzheimer disease (AD). While typically measured in plasma, serum is a widely used matrix in clinical laboratories, yet few p-tau217 assays have been validated for serum. Evaluating serum p-tau217 performance … Read more

Clin Chem. 2025 Nov 12:hvaf121. doi: 10.1093/clinchem/hvaf121. Online ahead of print. ABSTRACT BACKGROUND: Several US states have per se laws using 2 or 5 ng/mL of delta-9-tetrahydrocannabinol (THC) as cutpoints for driving under the influence of cannabis, while some have zero-tolerance statutes. These cutpoints are considered prima facia evidence of driving impairment. METHODS: In a … Read more

Clin Chem. 2025 Nov 11:hvaf147. doi: 10.1093/clinchem/hvaf147. Online ahead of print. ABSTRACT BACKGROUND: The increasing reports of xylazine in clinical and postmortem toxicology necessitate a survey of its clinical impact. This review examines reports of xylazine across the peer-reviewed literature and grey literature (government and public health reports). CONTENT: Before 2005, reports of xylazine abuse … Read more

Clin Chem. 2025 Nov 7:hvaf136. doi: 10.1093/clinchem/hvaf136. Online ahead of print. ABSTRACT BACKGROUND: Duchenne and Becker muscular dystrophies are X-linked neuromuscular disorders caused by mutations in the dystrophin gene (DMD). Duplications account for approximately 10% of pathogenic variants, but their structural complexity and variable clinical impact present significant challenges in pathogenicity interpretation. METHODS: We retrospectively … Read more